Onxeo Financial Statements From 2010 to 2024
| C4X Stock | EUR 0.11 0.01 8.33% |
Check Onxeo SA financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Onxeo main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Onxeo financial statements analysis is a perfect complement when working with Onxeo SA Valuation or Volatility modules.
Onxeo |
Onxeo SA Company Current Valuation Analysis
Onxeo SA's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Onxeo SA Current Valuation | 5.34 M |
Most of Onxeo SA's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Onxeo SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Onxeo SA has a Current Valuation of 5.34 M. This is 99.96% lower than that of the Healthcare sector and 99.88% lower than that of the Biotechnology industry. The current valuation for all Germany stocks is 99.97% higher than that of the company.
Onxeo SA Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Onxeo SA's current stock value. Our valuation model uses many indicators to compare Onxeo SA value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Onxeo SA competition to find correlations between indicators driving Onxeo SA's intrinsic value. More Info.Onxeo SA is rated third in return on equity category among related companies. It is rated third in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Onxeo SA by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Onxeo SA's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Onxeo SA's earnings, one of the primary drivers of an investment's value.About Onxeo SA Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Onxeo SA income statement, its balance sheet, and the statement of cash flows. Onxeo SA investors use historical funamental indicators, such as Onxeo SA's revenue or net income, to determine how well the company is positioned to perform in the future. Although Onxeo SA investors may use each financial statement separately, they are all related. The changes in Onxeo SA's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Onxeo SA's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Onxeo SA Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Onxeo SA. Please read more on our technical analysis and fundamental analysis pages.
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 29 people.
Pair Trading with Onxeo SA
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onxeo SA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onxeo SA will appreciate offsetting losses from the drop in the long position's value.Moving against Onxeo Stock
| 0.63 | NOVA | Novo Nordisk AS | PairCorr |
| 0.57 | DBPE | Xtrackers LevDAX | PairCorr |
| 0.55 | MBG | Mercedes Benz Group Earnings Call This Week | PairCorr |
| 0.51 | BZG2 | PT Bank Central | PairCorr |
The ability to find closely correlated positions to Onxeo SA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onxeo SA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onxeo SA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onxeo SA to buy it.
The correlation of Onxeo SA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onxeo SA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onxeo SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onxeo SA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Onxeo SA Correlation against competitors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Onxeo Stock analysis
When running Onxeo SA's price analysis, check to measure Onxeo SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Onxeo SA is operating at the current time. Most of Onxeo SA's value examination focuses on studying past and present price action to predict the probability of Onxeo SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Onxeo SA's price. Additionally, you may evaluate how the addition of Onxeo SA to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |